Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | KCNK3 | O14649 | 4/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ASPH | Q12797 | 1/20 | 0.30 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30598730 | 0.98 | ALDH1A1 (0.33) | KCNA5KCNH2HRH3KCNK3ALDH1A1 | |
| SCHEMBL13075730 | 0.78 | KDM4E (0.32) | KCNK3KDM4EASPHKDM8 | |
| SCHEMBL22105074 | 0.77 | HDAC6 (0.33) | — | |
| SCHEMBL2323123 | 0.75 | KCNA5 (0.47) | KCNA5KCNH2HRH3ALDH1A1LMNA | |
| SCHEMBL24214645 | 0.74 | HDAC6 (0.32) | — | |
| SCHEMBL24214744 | 0.72 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL12464828 | 0.70 | TSHR (0.34) | KCNA5KCNH2ALDH1A1 | |
| SCHEMBL18432377 | 0.70 | — | — | |
| SCHEMBL19841795 | 0.70 | — | — | |
| SCHEMBL15166345 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3894413-B1 | PYRAZOLOPYRIMIDINE PDE9 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-11-15 | — | — | EP | disclosed |
| US-20220017526-A1 | PYRAZOLOPYRIMIDINE PDE9 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2022-01-20 | — | — | US | disclosed |
| WO-2010131147-A1 | CYCLOBUTENEDIONE DERIVATIVES | PFIZER LIMITED (GB) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017526-A1 | PYRAZOLOPYRIMIDINE PDE9 INHIBITORS | PDE9A, PDE5A, PDE12 | KCNA5 316/4885KCNH2 492/4885HRH3 2166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.